Merck pips Novartis in MET race

Competition in the MET inhibitor space for non-small cell lung cancer (NSCLC) is heating up in Australia with Merck's Tepmetko finally provisionally approved this week as Novartis closes in with its candidate.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here